FDA advisers urge approval of Exubera, Pfizer promises monitoring plan

09/9/2005 | CNNMoney · Wall Street Journal, The

An FDA advisory panel recommended the agency give its approval to an insulin inhalant, Exubera, developed by Pfizer, Nektar Therapeutics and Sanofi-Aventis for diabetics. Pfizer said it was ready to begin a patient-monitoring plan to track the safety of the product, considered by the industry to have sales possibilities of $2 billion a year.

View Full Article in:

CNNMoney · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC